Form 4: Vir Biotechnology Director Acquires 16,000 Shares and Stock Options

Director Norbert W. Bischofberger acquired 16,000 shares of common stock and stock options in Vir Biotechnology, Inc. on May 29, 2024.

Summary

• On May 29, 2024, Norbert W. Bischofberger, a director of Vir Biotechnology, Inc., acquired 16,000 shares of common stock.
• The acquisition was made at a price of $0 per share.
• Following the transaction, Bischofberger directly owns 16,000 shares of Vir Biotechnology, Inc.
• Bischofberger also acquired stock options to purchase 16,000 shares of common stock with an exercise price of $10.10.
• 1/3 of the shares subject to the stock option vest and become exercisable on May 29, 2025, and the remaining shares vest in 24 equal monthly installments thereafter.
• Shares subject to the stock option vest and become exercisable on the earlier of (i) May 29, 2025, or (i) the date of the Company's next annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options suggests confidence, but it's a routine transaction.

Positives

• A director's acquisition of shares and stock options could be interpreted as a positive signal about their confidence in the company's future prospects.

Future Outlook

The vesting schedule of the stock options extends into the future, indicating a long-term perspective from the director.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates a director's continued investment in Vir Biotechnology.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis.
• Comparing the size and frequency of insider buys and sells at Vir Biotechnology to those of its peers (e.g., Gilead Sciences, Regeneron Pharmaceuticals) can provide insights into relative valuation and management confidence.
• The vesting schedule of the options is fairly standard, similar to equity grants at other biotech companies like Amgen or Biogen.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates